



**FLEX**  
G R O U P

Investor Presentation June 2010



## Forward-Looking Statements

The statements in this presentation that relate to the company's expectations with regard to the future impact on the company's results from acquisitions or actions in development are forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. Since the information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. Flex Fuels Energy, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

Full company information can be found here [http://www.flexgp.com/site/sec\\_filings](http://www.flexgp.com/site/sec_filings)



- To maximize shareholder value by investing in the booming healthcare market for Point-of-Care rapid medical diagnostics
- Complete corporate turn-around plan by divesting of underperforming assets and leveraging strong cash position into company's main focus in medical diagnostics market



- Point-of-Care diagnostic testing market forecast to grow by 7% in 2010 to \$13.9bn globally
- IP portfolio including 3 patents and a further 3 patent applications; proven technology; strong management team.
- Point-of-Care diagnostics sector M&A activity \$5.6 billion in Q3 2009, up 154% over prior year period
- Average P/E ratios of medical equipment companies acquired in Q3 2009 was 16 times
- Flex currently has group cash in excess of \$5 million (to be deployed into high ROI markets)
- Turnaround plan includes further development and (modest) investments in Wocu™ “World Currency” opportunity with intention to build value until profitable strategic divestment



- Ticker: FXFL
- Exchange: OTCBB
- Stock Price: \$0.09 (as of 5/10/10)
- Shares Outstanding: 44.5 Million
- Market Cap: \$4 Million
- Group Cash Position: in excess of \$5 million
- Management Stock Purchases: 403,000 shares bought in 2010 on open market
- Flex Group Share Buybacks: 24.8 million shares bought back in 2009, reduced shares outstanding by 36%
- Approx 10 m management warrants outstanding, 50% vesting over time (to 2011) and 50% on share price triggers, 45c & 90c

- Flex Group invests into Bio-Alternative Medical Devices in March 2010
- Medical diagnostics to be core business of Flex Group going forward
- Acquires 63% stake for approximately \$1.3 Million
- Purchase price to be applied to development of business
- Portfolio of 6 patents; 3 issued and 3 pending
- Management team with proven record of developing & commercializing medical diagnostics
- Commercialization strategy underway to secure development programs and sales with major healthcare industry partners





**FLEX**  
G R O U P



## The Market

- \$12.6 Billion Point-of-Care medical diagnostics global market in 2009.
- Market expected to grow 7% in 2010
- Growing demand for low-cost, hand held, point-of-care diagnostics to replace & complement clinical testing
- Global drive to reduce healthcare costs, and improve patient testing and monitoring of critical conditions and diseases
- Increasingly sophisticated patient population seeks immediate answers



**FLEX**  
G R O U P



Products

Bio-AMD has three key product areas:

- Digital Strip Reader with its first application into the digital home pregnancy test market; and with further application to other markets e.g. infectious diseases
- Blood coagulation monitoring device using prothrombin time monitor
- Magnetic Particle Reader Device; platform diagnostic technology for multiple applications, including cardio, oncology and infectious diseases



**FLEX**  
G R O U P



## Digital Strip Reader

### Digital Strip Reader applied to Home Pregnancy Test Market

- Global market for HPT is estimated 150 million tests per year
- Advantages over current technology on market:
  - ✓ Lower manufacturing costs
  - ✓ Quantitative measure of pregnancy “weeks since pregnancy”
  - ✓ Environmentally friendly = lower power requirement = lower costs; powered by solar, electro-chemical or electro-mechanical sources
  - ✓ Higher accuracy
  - ✓ Lower cost
- Technology highly attractive to potential licensees



**FLEX**  
G R O U P



BIO-AMD  
Bio-Alternative Medical Devices

## Blood Coagulation PT Monitor

PT Monitor used to test for blood clot formation (INR)

- Current market is 40 million tests per year
- Advantages over current technology on market:
  - ✓ Requires a 10<sup>th</sup> of the sample blood that competing products need to diagnose, leading to greater patient comfort
  - ✓ High accuracy
  - ✓ Reduced manufacturing costs due to fewer parts
  - ✓ Higher accuracy
  - ✓ Easier patient use with greater comfort
- Monitor to be used by patients taking anti-coagulant drugs, currently a \$4 billion market with double digit annual growth
- Low cost monitor to complement this growing market



**FLEX**  
G R O U P



## Magnetic Particle Reader

Magnetic Particle Reader capable of detecting nano-particles in Point-of-Care tests – Totally Novel Application

- Applications in vast markets both current and new
- Opens possibility for early detection in POC & OTC tests for cancer and heart disease
- Ability to challenge 'gold standard' laboratory test with lower cost, rapid POC tests
- Low cost device with disposable strips creating repeat business from disposables
- Target markets include detection of infectious diseases and drug abuse



**FLEX**  
G R O U P

## Growth: Medical Diagnostics Business



Flex Group's core focus is medical diagnostics

- Organic growth through development, licensing and Commercialization of Bio-AMD products
- Potential acquisition of complementary technologies and companies
- Potential spin out of technologies and products when maximum value add has been achieved



**FLEX**  
G R O U P

## Turnaround Structure

Flex Group is maximizing shareholder value through new focus on medical diagnostics and further value build in WDX;



Core for development & expansion,  
potentially by acquisition



For value build and  
reduction in control  
over time



**FLEX**  
G R O U P



## Currency Risk Neutralizer

- Wocu™, WDX derivative product, effectively a virtual “World Currency”
- Wocu™ quotation is derived by an algorithm inputting the top 20 world economies’ currency pair market prices, weighted by IMF GDP, outputted in real time
- Wocu™ is less volatile against national currencies compared to individual currency pairs
- Wocu™ offers reduced risk and hedging costs
- Wocu™ pricing of oil, metals and soft commodities an attractive alternative to using US\$ or Euro



**FLEX**  
G R O U P



# Value Add Strategy

- Establish commercial relationships with global banks and exchanges for Wocu™ trading
- U.S. patent for Technology & Method applied for September 2009
- International patent expected to be applied for September 2010
- Live Wocu™ price now outputted as live product
- Commercial discussions under way with numerous parties, first “proof of concept” contract signed
- Bunker Oil marine fuel is first commodity in world to be priced in Wocus

Indicative Spot FX Rates:		
	Currency	1 Wocu
	USD	1.6881 ▲
	EUR	1.2786 ▼
	JPY	157.46
	CNY	11.5222 ▼
	GBP	1.1088 ▲
	RUB	49.5663
	BRL	2.9875 ▲
	CAD	1.7139 ▲
	INR	75.3409
	MXN	20.8598
	AUD	1.8327 ▲
	KRW	1890.36
	TRL	2.5405 ▼
	PLN	5.0312 ▲
	IDR	15384.62

Rates are quoted as:  
- 1 Wocu = n units of Currency

Rates are:  
- delayed by 15 minutes and update every 5 seconds

Rates are calculated & distributed by:  
- WDX Organisation, London

Last Update: 07:47:48 UTC



- Medical diagnostics revenues:
  - Licensing revenues from strategic partners that are global leaders in healthcare (co-development products)
  - Sales revenues from products brought directly to market
- Profitable spin out or sale of WDX following further value build



**Tom Barr – CEO:** has served as a director of the Company since December 2006 and is now responsible for the turnaround and development of Flex Group's new strategy and its execution. Mr. Barr previously acted for private and public enterprises regarding prospective funding, investor and public relations strategy, including a fully listed London Stock Exchange company. Mr. Barr holds a BSc in biology and management science.

**Robert Galvin – CFO:** Former director at Arthur Andersen in the Corporate Finance practice area, responsible for group operations and development of the business unit globally. Founding partner in the ARM Partnership, a small corporate finance boutique, in which he has provided corporate and financial advice to a number of small cap, venture backed fast growth businesses. Extensive experience of M&A, divestments and general corporate finance. He has a first class BA (Hons) degree, and is an Associate of the Chartered Institute of Bankers (ACIB).

**David Miller – President and Secretary:** Mr. Miller has served as Company president since June 2009 and as a director since December 2008. He has expertise in corporate management, development and implementation of business plans and strategies as well as human resources planning. This experience has been gained at large corporates (Barclays Bank PLC where he worked and held senior positions over a period of 20 years) as well as at entrepreneurial enterprises (as Sales and Marketing Director for both MailSource UK Ltd and Secure Mail Services Ltd). He has also provided consultancy services to a venture capital provider. He is an Associate of the Chartered Institute of Bankers (ACIB).



**FLEX**  
G R O U P



## BioAMD Technical Management

**Dr Nasr Djennati, MD:** UMIST graduate with extensive experience in instrumentation design, analogue and digital electronics, information technology, sensors design (bio-sensors) and specifically in magnetic nano-particle applications within the medical point of care devices arena. 20 years experience in Hall Effect technology and Magnetic Field measurement and associated applications. Designed and successfully managed a novel POC Prothrombin device from its original idea to manufacturing status for a major Bio-Medical firm. Delivered a fully functional bench demonstrator to the customer in six months. Nasr also brings specific expertise to Bio-AMD in terms of production engineering, component sourcing and supplier management. Nasr has extensive contacts and experience of dealing with suppliers in China that will be crucial in the cost effective development of Bio-AMD's product pipeline.

**Dr Andy Mitchell, CTO:** UMIST graduate with a background in the Aerospace and Energy Generation sectors, Andy has a proven track record in design and implementation of a range of high specification, complex electronics and data communication systems operating to strict safety and type approval standards. Extensive knowledge of analogue, digital and hybrid electronics. Complete system design ability with unique skills in software/firmware development on a wide range of platforms. Successfully achieved MHRA approval for a device used in a clinical study undertaken for a previous employer. Andy brings specific expertise to Bio-AMD in terms of system specification, development and integration. His unique blend of electronics design and software skills ensure that products meet regulatory requirements whilst maintaining reliability and ease of use for the end user.



**FLEX**  
G R O U P



**BIO-AMD**  
Bio-Alternative Medical Devices

Opportunity

- Point-of-Care medical diagnostics is a rapidly growing \$12.6 billion global market – Core business
- Management team with expertise and track record in commercializing medical diagnostics
- Strong cash position
- Turn around strategy well underway
- Recent share buyback and management share purchases